CC BY-NC-ND 4.0 · Laryngorhinootologie 2020; 99(S 02): S155
DOI: 10.1055/s-0040-1710998
In-vitro targeted alpha-particle therapy (TAT) with 213Bi-Cetuximab outperforms X-Ray irradiation independent of HPV status of HNSCC cell lines
M Siegl
1
Technische Universität München, Department of Otolaryngology Head and Neck Surgery München
,
C Seidl
2
Technische Universität München, Department of Nuclear Medicine München
,
F Bruchertseifer
3
European Commission, JRC, Directorate for Nuclear Safety and Security Karlsruhe
,
A Morgenstern
3
European Commission, JRC, Directorate for Nuclear Safety and Security Karlsruhe
,
U Zissler
4
Technische Universität München und Helmholtz Zentrum München, Center of Allergy & Environment (ZAUM) München
,
G Multhoff
5
Technische Universität München, Center for Translational Cancer Research (TranslaTUM) München
,
B Wollenberg
1
Technische Universität München, Department of Otolaryngology Head and Neck Surgery München
,
A Pickhard
1
Technische Universität München, Department of Otolaryngology Head and Neck Surgery München
› Institutsangaben
